SEP 28, 2021 8:00 AM PDT

Cell Therapy Scrubs Tumors, Spares Transplanted Organs

WRITTEN BY: Tara Fernandes

Hepatitis B infections have created a ‘silent epidemic’—infected people don’t display any symptoms, and as a consequence, unknowingly pass the virus on to others. The signs of hepatitis B virus (HBV) infection only manifest years after the initial infection. Many patients present with a common form of liver cancer called hepatocellular carcinoma or HCC.

At this critical stage, liver transplants provide HCC patients with the best hope. However, traces of the HBV in circulation still linger, which can return with a vengeance, only to reignite cancer in the newly-transplanted liver. 

Consequently, HBV-positive HCC patients who have received liver transplants have very few viable options to keep them cancer-free. This is partly because these individuals need to take a life-long regimen of immunosuppressive drugs to prevent their immune systems from rejecting the donor organ.

Cell therapies using reprogrammed T cells are available clinically—the patient’s immune cells are directed to target and eliminate tumor cells. However, immunosuppressive drugs taken by HCC patients would not discriminate against these ‘good’ immune cells, disarming them and reducing the efficacy of T cell therapies.

Now, researchers have developed T cell soldiers with specialized skills and strong, protective shields. A team led by Antonio Bertoletti from the Singapore Immunology Network (SIgN), developed next-generation T cell therapies that are resistant to immunosuppressive drugs. These unique T cells have been genetically manipulated such that they recognize and target liver cancer cells that contain fragments of HBV proteins. 

In their study, the researchers found that the commonly prescribed immunosuppressive drugs (tacrolimus and mofetil) were toxic to first-generation T cell therapies. However, by equipping T cells with a specific panel of genes, the turbocharged next-generation cells could maintain their cancer-killing capabilities even in the presence of harsh immunosuppressants.

This discovery paves the way for a new class of T cell therapies for HBV-positive patients with HCC that can eliminate tumors while leaving healthy liver tissues untouched.


 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
FEB 10, 2022
Immunology
RNA Spray Prevents Long COVID
FEB 10, 2022
RNA Spray Prevents Long COVID
  Millions of people are experiencing lingering effects of COVID-19 that continue long after the initial infection ...
FEB 10, 2022
Immunology
Fresh Insights Into Gut Inflammation
FEB 10, 2022
Fresh Insights Into Gut Inflammation
We live in harmony with around 200 trillion microorganisms that make up the human microbiome. These friendly microbes he ...
MAR 20, 2022
Health & Medicine
Could a Newly Identified Killer T Cell Offer Insight into How We Treat Autoimmune Diseases in the Future?
MAR 20, 2022
Could a Newly Identified Killer T Cell Offer Insight into How We Treat Autoimmune Diseases in the Future?
Scientists have investigated the role of regulatory T cells in autoimmune disease. Regulatory T cells carry the CD4 prot ...
APR 08, 2022
Immunology
How Zinc Can Boost the Function of the Immune System
APR 08, 2022
How Zinc Can Boost the Function of the Immune System
Zinc is a mineral that's known to boost the function of the immune system, and now scientists have learned more about ho ...
APR 20, 2022
Cancer
A Specialized Mouse Model Identifies Genetic Regulators of Immunotherapy Response
APR 20, 2022
A Specialized Mouse Model Identifies Genetic Regulators of Immunotherapy Response
Recent advances in immune checkpoint inhibitors (ICI) have led to significant clinical benefits for patients with variou ...
APR 28, 2022
Immunology
Lipid Supplement May Reduce Inflammation in MS
APR 28, 2022
Lipid Supplement May Reduce Inflammation in MS
Administration of an inflammation-mediating lipid has shown promise in reducing multiple sclerosis-related inflammation ...
Loading Comments...